BioWorld looks at translational medicine, including: Potassium channel distancing fights stroke; ASO approach fixes myelin; FMF is Mediterranean’s SCD; Calpain-2 in common, rare neurodegeneration; Antitoxin vaccine fights S. aureus; Noncoding mutations contribute to heart disease; Good vs. evil in the synovial joint; Necrosis has role in post-flu bacterial infections; Macrophage crosstalk inflames fat.
Keeping you up to date on recent developments in oncology, including: New microfluidic platform enables deeper analysis of role of angiogenesis in cancer; P53 'glue' gums up cancer cells; New blood test could aid in hepatocellular carcinoma screening.
Two separate groups have recently shown that in mouse models, inactivation of a single gene was enough to directly convert other cell types in the brain into neurons.
Technical challenges at the annual meeting of the International Society for Stem Cell Research (ISSCR) meeting led to at least one lively exchange of stem cell jokes in the chat box as the audience waited for talks to resume, including stem cell parental advice: “You can be anything you want when you grow up!”
BioWorld looks at translational medicine, including: A Tau-sand forms of tau?; P53 ‘glue’ gums up cancer cells; Shock and kill with less toxicity; Placental attachment theory.
Keeping you up to date on recent developments in diagnostics, including: Border detection algorithm for melanoma; Predicting future suicide risk; Multiracial study gives new diabetes insights; Patient genetic variants linked to wound microbiomes.
By targeting chimeric antigen receptors (CARs) to a senescence marker, researchers at Memorial Sloan-Kettering Cancer Center have developed a CAR T cell that had beneficial effects in mouse models of both liver fibrosis and lung cancer.
By targeting chimeric antigen receptors (CARs) to a senescence marker, researchers at Memorial Sloan-Kettering Cancer Center have developed a CAR T cell that had beneficial effects in mouse models of both liver fibrosis and lung cancer.
On June 17, the FDA approved checkpoint blocker Keytruda (pembrolizumab, Merck & Co. Inc.) “for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [?10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.”
BioWorld looks at translational medicine, including: Liver-derived protein helps lung, kidney repair; Multiracial study gives new diabetes insights; New way to target drugs, independently of drug target; Microbiome-produced metabolites improve gut health; Universal flu vaccine more challenging than anticipated; The bow ties that bind; FOXO1 regulates HIV latency; Patient genetic variants linked to wound microbiomes; New COPD target.
